

# ASX ANNOUNCEMENT

23 November 2020

## **DurAVR™ SELECTED AS A “BEST INNOVATION” AT THE LEADING INTERNATIONAL INTERVENTIONAL CARDIOVASCULAR CONFERENCE**

**Brisbane, Australia and Minneapolis USA**, Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company), is pleased to advise that its 3D single-piece aortic valve DurAVR™ has been selected as a “Best Innovation” at the PCR London Valves 2020 virtual conference, with data from the company’s first-in-human trial to be presented.

PCR London Valves is the world’s largest educational meeting focused on transcatheter therapies for valvular heart disease. It attracts interventional cardiologists, cardiac surgeons, heart teams and industry partners committed to the field of structural heart solutions.

Presentations for “Best Innovation” are selected in a competitive, peer-reviewed process. Anteris’ DurAVR™ is the only aortic valve being featured in the Best Innovations section.

Professor Bart Meuris MD, PhD, Chief of Cardiovascular Surgery at the University Hospitals, Leuven, Belgium and Principal Investigator of the company’s first-in-human study will present on Anteris’ behalf, and provide an overview of the DurAVR™ heart valve and results generated to date in the first-in-human study.

The PCR London Valves meeting is held 22-24 November 2020 and is being conducted as a virtual meeting this year given the current COVID-19 restrictions.

“To be featured as a Best Innovation at PCR London Valves is a highly coveted honor, with all entries reviewed by a panel of independent experts. To be selected speaks to the quality of the clinical and pre-clinical evidence demonstrating the superior performance and durability of DurAVR™ and the genuine interest in its potential to significantly improve outcomes for patients,” said Wayne Paterson, CEO of Anteris Technologies.

### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

**Anteris Technologies Ltd**

**Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

**Customer Service:**

T +61 1300 550 310 | F +61 1300 972 437 | E [info@anteristech.com](mailto:info@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga





The proven benefits of its ADAPT® tissue technology, paired with the unique 3D single piece aortic valve design of DurAVR™, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

**Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

**For more information:**

Ms Kyahn Williamson

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 401 018 828

[www.anteristech.com](http://www.anteristech.com)

Twitter: @AnterisTech

Facebook: [www.facebook.com/AnterisTech](http://www.facebook.com/AnterisTech)